Q2 26 EPS
$0.86
BEAT +3.85%
Est. $0.83
Q2 26 Revenue
$5.44B
BEAT +1.42%
Est. $5.37B
vs S&P Since Q2 26
+0.0%
BEATING MARKET
BSX +6.0% vs S&P +6.0%
Market Reaction
Did BSX Beat Earnings? Q2 2026 Results
Boston Scientific posted a clean beat across both top and bottom lines in Q2 2026, extending its EPS consensus beat streak to five consecutive quarters as adjusted earnings of $0.86 per share cleared the $0.83 estimate by 3.86% and rose sharply from … Read more Boston Scientific posted a clean beat across both top and bottom lines in Q2 2026, extending its EPS consensus beat streak to five consecutive quarters as adjusted earnings of $0.86 per share cleared the $0.83 estimate by 3.86% and rose sharply from $0.75 in the year-ago period. Revenue of $5.44 billion grew 7.5% year over year, edging past the $5.37 billion consensus by 1.42%, with the Cardiovascular segment serving as the primary engine, delivering 8.3% reported sales growth and helping lift GAAP net income to $907 million, or $0.61 per diluted share, from $797 million a year ago. A standout within the broader portfolio was the Neuromodulation business, which grew 12.7% on a reported basis, while the FARAPULSE pulsed field ablation system continued to generate positive clinical momentum. The strong quarter arrives alongside a global restructuring plan targeting $500 million in annual cost savings, as management looks to sharpen its operational profile; for full-year 2026, Boston Scientific guided for organic revenue growth of 5% to 6% and adjusted EPS of $3.28 to $3.32.
Key Takeaways
- • Cardiovascular segment growth of 8.3% reported driven by strong demand
- • Neuromodulation growth of 12.7% reported was the fastest growing product line
- • Asia Pacific region grew 11.2% and Latin America/Canada grew 22.4% on a reported basis
- • Category leadership strategy and disciplined execution across the portfolio
BSX Forward Guidance & Outlook
For full year 2026, Boston Scientific estimates net sales growth of approximately 5.5% to 6.5% on a reported basis and 5% to 6% on an organic basis, with adjusted EPS of $3.28 to $3.32. For Q3 2026, the company estimates net sales growth of approximately 3% to 5% on both a reported and organic basis, with adjusted EPS of $0.80 to $0.82.
BSX YoY Financials
Q2 2026 vs Q2 2025, source: SEC Filings
BSX Revenue by Segment
With YoY comparisons, source: SEC Filings
BSX Revenue by Geography
With YoY comparisons, source: SEC Filings
“Our team delivered a solid quarter while continuing to navigate a dynamic environment. We are focused on disciplined execution and prioritizing investments in our highest-impact opportunities, and we remain confident in Boston Scientific's long-term growth, anchored by our category leadership strategy and our commitment to meaningful innovation for patients and physicians.”
— Mike Mahoney, Q2 2026 Earnings Press Release
BSX Earnings Trends
BSX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
BSX EPS Trend
Earnings per share: estimate vs actual
BSX Revenue Trend
Quarterly revenue: estimate vs actual
BSX Quarterly Results
6 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 BEAT | $0.83 | $0.86 | +3.85% | $5.44B | +1.42% |
| Q1 26 BEAT | $0.79 | $0.80 | +1.27% | $5.20B | +0.60% |
| Q4 25 BEAT FY | $0.78 | $0.80 | +2.56% | $5.29B | +0.04% |
| FY Full Year | $3.04 | $3.06 | +0.80% | $20.07B | +0.01% |
| Q3 25 BEAT | $0.71 | $0.75 | +5.63% | $5.07B | +1.83% |
| Q2 25 BEAT | $0.73 | $0.75 | +2.74% | $5.06B | +3.39% |
| Q1 25 BEAT | $0.67 | $0.75 | +11.94% | $4.66B | +1.98% |